Exact Sciences(EXAS)
(EXAS)
Q4-rapport
59 dagar sedan‧1t 1min
Orderdjup
Stängd
Antal
Köp
0
Sälj
Antal
0
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| - | - | - | - |
Volymvägt snittpris (VWAP)
-VWAP
-Omsättning (USD)
132 854 534Mäklarstatistik
Ingen data hittades
Företagshändelser
| Nästa händelse | |
|---|---|
| 2024 Q1-rapport | 8 maj |
| Tidigare händelser | ||
|---|---|---|
| 2023 Q4-rapport | 21 feb. | |
| 2023 Årsrapport | 21 feb. | |
| 2023 Q3-rapport | 1 nov. 2023 | |
| 2023 Q2-rapport | 1 aug. 2023 | |
| 2023 Årsstämma | 8 juni 2023 |
Data hämtas från Morningstar, Quartr
Nyheter & Analyser
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Q4-rapport
59 dagar sedan‧1t 1min
Nyheter & Analyser
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Företagshändelser
| Nästa händelse | |
|---|---|
| 2024 Q1-rapport | 8 maj |
| Tidigare händelser | ||
|---|---|---|
| 2023 Q4-rapport | 21 feb. | |
| 2023 Årsrapport | 21 feb. | |
| 2023 Q3-rapport | 1 nov. 2023 | |
| 2023 Q2-rapport | 1 aug. 2023 | |
| 2023 Årsstämma | 8 juni 2023 |
Data hämtas från Morningstar, Quartr
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
28 mars28 marsExact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer. Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early. Source: Business Wire- 19 nov. 2023 · Ändrad19 nov. 2023 · ÄndradProfitability Is Still Two Years Out. Today (Nov. 1, 2023), Exact Sciences is still reporting losses. But that's expected to change in 2025. At that point, analysts polled by FactSet expect the company to report an adjusted gain of 56 cents per share. Sales in 2023-25 are expected to grow 13%-15%. EXAS stock also has a nearly perfect Relative Strength Rating of 98. This puts shares in the top 2% of all stocks in terms of 12-month performance, according to IBD Digital. Shares also have a strong Composite Rating of 95, meaning EXAS stock outranks 95% of all stocks when it comes to fundamental and technical measures. Source: https://www.investors.com/news/technology/exas-stock-why-this-top-stock-is-on-an-eight-month-hot-streak/
- 5 nov. 20235 nov. 2023WHY EXAS COULD SOON BECOME PROFITABLE. "Looking forward, it remains to be seen if the robust Cologuard business momentum will continue or if the company's rising expenditures will pressure (or limit) margins in the near term," Canaccord's Mikson said. He kept his buy rating and 120 price target on EXAS stock. This is the first quarter since March 2021 that Exact Sciences hasn't reported an adjusted loss. Sales climbed 20% year over year. In the September quarter, sales in Exact Sciences' screening division surged 31% to $472 million. That beat EXAS stock analysts' view by $10 million, according to FactSet. The screening segment includes primarily laboratory service revenue from Cologuard and blood-based genetic tests that screen for hereditary forms of cancer called PreventionGenetics. "The solid results were driven by continued Cologuard volume growth, with revenue from this product increasing roughly 30% year over year," Canaccord Genuity analyst Kyle Mikson said in a report to clients. Source: https://www.investors.com/news/technology/exas-stock-why-this-large-cathie-wood-holding-could-soon-be-profitable/
- 23 juni 202323 juni 2023"Exact Sciences (EXAS) could eventually nab half of the colon cancer screening market, an analyst said after the company's next-generation Cologuard beat the original product in a study of 20,000 people." https://www.investors.com/news/technology/exas-stock-has-surged-since-october-why-this-news-could-stoke-it-again/?src=A00220
Brøt denne akkurat ut av den fallende trenden nå?
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Q4-rapport
59 dagar sedan‧1t 1min
Nyheter & Analyser
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
- 28 mars28 marsExact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer. Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early. Source: Business Wire
- 19 nov. 2023 · Ändrad19 nov. 2023 · ÄndradProfitability Is Still Two Years Out. Today (Nov. 1, 2023), Exact Sciences is still reporting losses. But that's expected to change in 2025. At that point, analysts polled by FactSet expect the company to report an adjusted gain of 56 cents per share. Sales in 2023-25 are expected to grow 13%-15%. EXAS stock also has a nearly perfect Relative Strength Rating of 98. This puts shares in the top 2% of all stocks in terms of 12-month performance, according to IBD Digital. Shares also have a strong Composite Rating of 95, meaning EXAS stock outranks 95% of all stocks when it comes to fundamental and technical measures. Source: https://www.investors.com/news/technology/exas-stock-why-this-top-stock-is-on-an-eight-month-hot-streak/
- 5 nov. 20235 nov. 2023WHY EXAS COULD SOON BECOME PROFITABLE. "Looking forward, it remains to be seen if the robust Cologuard business momentum will continue or if the company's rising expenditures will pressure (or limit) margins in the near term," Canaccord's Mikson said. He kept his buy rating and 120 price target on EXAS stock. This is the first quarter since March 2021 that Exact Sciences hasn't reported an adjusted loss. Sales climbed 20% year over year. In the September quarter, sales in Exact Sciences' screening division surged 31% to $472 million. That beat EXAS stock analysts' view by $10 million, according to FactSet. The screening segment includes primarily laboratory service revenue from Cologuard and blood-based genetic tests that screen for hereditary forms of cancer called PreventionGenetics. "The solid results were driven by continued Cologuard volume growth, with revenue from this product increasing roughly 30% year over year," Canaccord Genuity analyst Kyle Mikson said in a report to clients. Source: https://www.investors.com/news/technology/exas-stock-why-this-large-cathie-wood-holding-could-soon-be-profitable/
- 23 juni 202323 juni 2023"Exact Sciences (EXAS) could eventually nab half of the colon cancer screening market, an analyst said after the company's next-generation Cologuard beat the original product in a study of 20,000 people." https://www.investors.com/news/technology/exas-stock-has-surged-since-october-why-this-news-could-stoke-it-again/?src=A00220
- Brøt denne akkurat ut av den fallende trenden nå?
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Orderdjup
Stängd
Antal
Köp
0
Sälj
Antal
0
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| - | - | - | - |
Volymvägt snittpris (VWAP)
-VWAP
-Omsättning (USD)
132 854 534Mäklarstatistik
Ingen data hittades
Företagshändelser
| Nästa händelse | |
|---|---|
| 2024 Q1-rapport | 8 maj |
| Tidigare händelser | ||
|---|---|---|
| 2023 Q4-rapport | 21 feb. | |
| 2023 Årsrapport | 21 feb. | |
| 2023 Q3-rapport | 1 nov. 2023 | |
| 2023 Q2-rapport | 1 aug. 2023 | |
| 2023 Årsstämma | 8 juni 2023 |
Data hämtas från Morningstar, Quartr